Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Oct;104(10):1972-1973.
doi: 10.1097/TP.0000000000003283.

Off-the-shelf EBV-specific T-cell Immunotherapy for EBV-associated PTLD

Maeve O'Reilly  1 , Karl S Peggs
Affiliations
Comment

Off-the-shelf EBV-specific T-cell Immunotherapy for EBV-associated PTLD

Maeve O'Reilly et al. Transplantation. 2020 Oct.
No abstract available

PubMed Disclaimer

Comment on

  • Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation.
    Prockop S, Doubrovina E, Suser S, Heller G, Barker J, Dahi P, Perales MA, Papadopoulos E, Sauter C, Castro-Malaspina H, Boulad F, Curran KJ, Giralt S, Gyurkocza B, Hsu KC, Jakubowski A, Hanash AM, Kernan NA, Kobos R, Koehne G, Landau H, Ponce D, Spitzer B, Young JW, Behr G, Dunphy M, Haque S, Teruya-Feldstein J, Arcila M, Moung C, Hsu S, Hasan A, O'Reilly RJ. Prockop S, et al. J Clin Invest. 2020 Feb 3;130(2):733-747. doi: 10.1172/JCI121127. J Clin Invest. 2020. PMID: 31689242 Free PMC article. Clinical Trial.

References

    1. Prockop S, Doubrovina E, Suser S, et al. Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation. J Clin Invest. 2020; 130:733–747doi:10.1172/JCI121127 - DOI
    1. Starzl TE, Nalesnik MA, Porter KA, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporine-steroid therapy. Lancet. 1984; 1:583–587doi:10.1016/s0140-6736(84)90994-2 - DOI
    1. Morscio J, Dierickx D, Tousseyn T. Molecular pathogenesis of B-cell posttransplant lymphoproliferative disorder: what do we know so far? Clin Dev Immunol. 2013; 2013:150835doi:10.1155/2013/150835 - DOI
    1. Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med. 1994; 330:1185–1191doi:10.1056/NEJM199404283301703 - DOI
    1. Heslop HE, Brenner MK, Rooney CM. Donor T cells to treat EBV-associated lymphoma. N Engl J Med. 1994; 331:679–680doi:10.1056/NEJM199409083311017 - DOI

LinkOut - more resources